Evidence map›Paper›PMID 42755744›Full record

ArticleFrontiers in cardiovascular medicine2026

Editorial: Therapeutic targeting of cell death in cardiovascular diseases: from mechanisms to clinical applications.

Haiyan Xiang, Mohammed Ben Issa, Keman Xu, Shih-Yu Hung, Ying Shao, Yifan Lu, Bo Yuan, Juanjuan Liu, Fatma Saaoud, Shafqat Ullah and 5 more

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Haiyan Xiang *Center for Metabolic Disease Research and Sol Sherry Thrombosis Research Center, Department of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Mohammed Ben Issa *Lemole Center for Integrated Lymphatics and Vascular Research, Department of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Keman XuLemole Center for Integrated Lymphatics and Vascular Research, Department of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Shih-Yu HungLemole Center for Integrated Lymphatics and Vascular Research, Department of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Ying ShaoLemole Center for Integrated Lymphatics and Vascular Research, Department of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Yifan LuLemole Center for Integrated Lymphatics and Vascular Research, Department of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Bo YuanLemole Center for Integrated Lymphatics and Vascular Research, Department of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Juanjuan LiuLemole Center for Integrated Lymphatics and Vascular Research, Department of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Fatma SaaoudLemole Center for Integrated Lymphatics and Vascular Research, Department of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Shafqat UllahCenter for Metabolic Disease Research and Sol Sherry Thrombosis Research Center, Department of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Juncheng WeiCenter for Metabolic Disease Research and Sol Sherry Thrombosis Research Center, Department of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Rihab BoucharebCenter for Metabolic Disease Research and Sol Sherry Thrombosis Research Center, Department of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Liya YinCollege of Medicine Phoenix, University of Arizona, Phoenix, AZ, United States.
Hong WangCenter for Metabolic Disease Research and Sol Sherry Thrombosis Research Center, Department of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Xiaofeng YangCenter for Metabolic Disease Research and Sol Sherry Thrombosis Research Center, Department of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.

Funding

LysoPI/GPR55 pathway promotes endothelial activation, vascular inflammation and atherosclerosisR01HL163570 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI Xiaofeng Yang · 2023 to 2026
$2.6M
NHLBI NIH HHS R01 HL163570
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cardiovascular diseasescell deathinflammationprecision medicinetherapeutics

Identifiers

PMID42755744
PMCPMC13581767

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.